

Josã© C Crispã-n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6027722/publications.pdf>

Version: 2024-02-01

107
papers

5,626
citations

71061

41
h-index

79644

73
g-index

112
all docs

112
docs citations

112
times ranked

6006
citing authors

#	ARTICLE	IF	CITATIONS
1	Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys. <i>Journal of Immunology</i> , 2008, 181, 8761-8766.	0.4	678
2	Quantification of regulatory T cells in patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2003, 21, 273-276.	3.0	379
3	Pathogenesis of human systemic lupus erythematosus: recent advances. <i>Trends in Molecular Medicine</i> , 2010, 16, 47-57.	3.5	311
4	T cells as therapeutic targets in SLE. <i>Nature Reviews Rheumatology</i> , 2010, 6, 317-325.	3.5	230
5	Interleukin-17 and systemic lupus erythematosus: current concepts. <i>Clinical and Experimental Immunology</i> , 2009, 157, 209-215.	1.1	193
6	Phosphatase PP2A is requisite for the function of regulatory T cells. <i>Nature Immunology</i> , 2016, 17, 556-564.	7.0	191
7	CaMK4-dependent activation of AKT/mTOR and CREM-1 underlies autoimmunity-associated Th17 imbalance. <i>Journal of Clinical Investigation</i> , 2014, 124, 2234-2245.	3.9	185
8	Human TCR-1 α ⁺ CD4 α ⁺ CD8 α ⁺ T Cells Can Derive from CD8 ⁺ T Cells and Display an Inflammatory Effector Phenotype. <i>Journal of Immunology</i> , 2009, 183, 4675-4681.	0.4	154
9	Stat3 promotes IL-10 expression in lupus T cells through <i>trans-</i> activation and chromatin remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13457-13462.	3.3	148
10	The Dysregulation of Cytokine Networks in Systemic Lupus Erythematosus. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 769-779.	0.5	120
11	IL-17-producing T cells in lupus nephritis. <i>Lupus</i> , 2011, 20, 120-124.	0.8	114
12	Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. <i>Lupus</i> , 2008, 17, 289-294.	0.8	112
13	Gene-function studies in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2013, 9, 476-484.	3.5	99
14	cAMP response element modulator 1 controls <i>IL2</i> and <i>IL17A</i> expression during CD4 lineage commitment and subset distribution in lupus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16606-16611.	3.3	92
15	How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. <i>Trends in Immunology</i> , 2008, 29, 110-115.	2.9	91
16	Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Lupus. <i>Journal of Immunology</i> , 2012, 189, 3490-3496.	0.4	91
17	Transcriptional regulation of IL-2 in health and autoimmunity. <i>Autoimmunity Reviews</i> , 2009, 8, 190-195.	2.5	89
18	Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. <i>Arthritis and Rheumatism</i> , 2011, 63, 523-529.	6.7	87

#	ARTICLE	IF	CITATIONS
19	Mechanisms of Tissue Injury in Lupus Nephritis. <i>Trends in Molecular Medicine</i> , 2018, 24, 364-378.	3.5	86
20	Rheumatologic manifestations of diabetes mellitus. <i>American Journal of Medicine</i> , 2003, 114, 753-757.	0.6	81
21	IL-17 in Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-4.	3.0	81
22	Interleukin-17-producing T cells in lupus. <i>Current Opinion in Rheumatology</i> , 2010, 22, 499-503.	2.0	80
23	IL-17 producing CD4 ⁺ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. <i>Clinical Immunology</i> , 2009, 130, 313-321.	1.4	77
24	Protein Phosphatase 2A Enables Expression of Interleukin 17 (IL-17) through Chromatin Remodeling. <i>Journal of Biological Chemistry</i> , 2013, 288, 26775-26784.	1.6	77
25	CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients. <i>British Journal of Cancer</i> , 2017, 117, 385-397.	2.9	77
26	Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. <i>Arthritis and Rheumatism</i> , 2010, 62, 1431-1437.	6.7	76
27	Adult-Onset Still Disease as the Cause of Fever of Unknown Origin. <i>Medicine (United States)</i> , 2005, 84, 331-337.	0.4	72
28	Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 101994-102005.	0.8	72
29	cAMP Responsive Element Modulator (CREM) $\hat{\pm}$ Mediates Chromatin Remodeling of CD8 during the Generation of CD3 ⁺ CD4 ⁺ CD8 ⁻ T Cells. <i>Journal of Biological Chemistry</i> , 2014, 289, 2361-2370.	1.6	66
30	ICER is requisite for Th17 differentiation. <i>Nature Communications</i> , 2016, 7, 12993.	5.8	64
31	KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3 ⁺ regulatory T cells in MRL/lpr mice. <i>Autoimmunity</i> , 2014, 47, 445-450.	1.2	60
32	Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. <i>Autoimmunity</i> , 2014, 47, 234-241.	1.2	59
33	cAMP-responsive Element Modulator $\hat{\pm}$ (CREM $\hat{\pm}$) trans-Represses the Transmembrane Glycoprotein CD8 and Contributes to the Generation of CD3 ⁺ CD4 ⁺ CD8 ⁻ T Cells in Health and Disease. <i>Journal of Biological Chemistry</i> , 2013, 288, 31880-31887.	1.6	53
34	Programmed Cell Death 1 and Helios Distinguish TCR- $\hat{\pm}$ ⁺ Double-Negative (CD4 ⁻ CD8 ⁻) T Cells That Derive from Self-Reactive CD8 T Cells. <i>Journal of Immunology</i> , 2015, 194, 4207-4214.	0.4	53
35	Moderate and severe neutropenia in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2006, 45, 994-998.	0.9	51
36	Cutting Edge: Protein Phosphatase 2A Confers Susceptibility to Autoimmune Disease through an IL-17 $\hat{\pm}$ -Dependent Mechanism. <i>Journal of Immunology</i> , 2012, 188, 3567-3571.	0.4	51

#	ARTICLE	IF	CITATIONS
37	Participation of the CD69 Antigen in the Tâ€Cell Activation Process of Patients with Systemic Lupus Erythematosus. <i>Scandinavian Journal of Immunology</i> , 1998, 48, 196-200.	1.3	50
38	Interleukin 2 and systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2009, 9, 34-39.	2.5	48
39	Induction of PP2A BÎ², a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12443-12448.	3.3	46
40	Human Neurocysticercosis: In Vivo Expansion of Peripheral Regulatory T Cells and Their Recruitment in the Central Nervous System. <i>Journal of Parasitology</i> , 2012, 98, 142-148.	0.3	45
41	The role myeloid dendritic cells play in the pathogenesis of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2007, 6, 450-456.	2.5	42
42	Novel molecular targets in the treatment of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2008, 7, 256-261.	2.5	41
43	B cells contribute to ischemia/reperfusion-mediated tissue injury. <i>Journal of Autoimmunity</i> , 2009, 32, 195-200.	3.0	39
44	Proâ€inflammatory selfâ€reactive Tâ€cells are found within murine TCRâ€Î±Î²⁺CD4^{â€}CD8^{â€}PDâ€1⁺ cells. <i>European Journal of Immunology</i> , 2016, 46, 1383-1391.	1.6	36
45	Letter to the Editor. <i>Lupus</i> , 2005, 14, 495-496.	0.8	35
46	T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis. <i>Clinical Immunology</i> , 2008, 128, 1-7.	1.4	34
47	CREMÎ± overexpression decreases IL-2 production, induces a TH17 phenotype and accelerates autoimmunity. <i>Journal of Molecular Cell Biology</i> , 2012, 4, 121-123.	1.5	34
48	A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. <i>Transplant Immunology</i> , 2007, 18, 166-171.	0.6	32
49	A Novel Inhibitor of the Alternative Pathway of Complement Attenuates Intestinal Ischemia/Reperfusion-Induced Injury. <i>Journal of Surgical Research</i> , 2011, 167, e131-e136.	0.8	30
50	Phenotype and function of dendritic cells of patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2012, 143, 45-50.	1.4	30
51	Class I and class II MHC polymorphisms in Mexican patients with Behçetâ€™s disease. <i>Immunology Letters</i> , 2004, 93, 211-215.	1.1	27
52	IL-10 production in B cells is confined to CD154+ cells in patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2004, 23, 379-383.	3.0	26
53	Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease. <i>Clinical Immunology</i> , 2015, 160, 286-291.	1.4	25
54	Ethical Considerations in Animal Research: The Principle of 3R's. <i>Revista De Investigacion Clinica</i> , 2021, 73, 199-209.	0.2	23

#	ARTICLE	IF	CITATIONS
55	Interleukin-2 and systemic lupus erythematosusâ€”fifteen years later. <i>Lupus</i> , 1998, 7, 214-222.	0.8	22
56	Systemic lupus erythematosus: new molecular targets. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, iii65-iii69.	0.5	22
57	Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission. <i>Lupus</i> , 2003, 12, 386-393.	0.8	21
58	Immunoregulatory T cells in autoimmunity. <i>Autoimmunity Reviews</i> , 2004, 3, 45-51.	2.5	21
59	SLE-Associated Defects Promote Altered T Cell Function. <i>Critical Reviews in Immunology</i> , 2017, 37, 39-58.	1.0	21
60	Regulation of activated T cell survival in rheumatic autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 232-244.	3.5	21
61	TCR-Î±/Î² CD4â€” CD8â€” double negative T cells arise from CD8+ T cells. <i>Journal of Leukocyte Biology</i> , 2020, 108, 851-857.	1.5	18
62	Common hematological values predict unfavorable outcomes in hospitalized COVID-19 patients. <i>Clinical Immunology</i> , 2021, 225, 108682.	1.4	18
63	Orbital and periorbital inflammation in VEXAS syndrome. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 338-341.	0.6	18
64	Quantitative and functional profiles of CD4+ lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia. <i>Clinical and Experimental Immunology</i> , 2011, 164, 17-25.	1.1	17
65	Neurocysticercosis: local and systemic immune-inflammatory features related to severity. <i>Medical Microbiology and Immunology</i> , 2012, 201, 73-80.	2.6	16
66	Acetylcholine-Esterase Inhibitor Pyridostigmine Decreases T Cell Overactivation in Patients Infected by HIV. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 749-755.	0.5	15
67	Gene-function studies in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2019, 31, 185-192.	2.0	14
68	PPP2R2B hypermethylation causes acquired apoptosis deficiency in systemic autoimmune diseases. <i>JCI Insight</i> , 2019, 4, .	2.3	14
69	<i>De Novo</i> Donor-Specific HLA Antibody Development and Peripheral< mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1">< mml:mrow>< mml:msup>< mml:mrow>< mml:mtext>CD4</mml:mtext></mml:mrow>< mml:mo>+</mml:mo></mml:msup></mml:mrow></i> in Kidney Transplant Recipients: A Place for Interaction?. <i>Journal of Transplantation</i> , 2012, 2012, 1-8.	0.3	13
70	Add-on Pyridostigmine Enhances CD4+ T-Cell Recovery in HIV-1-Infected Immunological Non-Responders: A Proof-of-Concept Study. <i>Frontiers in Immunology</i> , 2017, 8, 1301.	2.2	13
71	Identification of regulatory T cell molecules associated with severity of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1695-1705.	1.4	13
72	A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol. <i>BMC Infectious Diseases</i> , 2020, 20, 765.	1.3	11

#	ARTICLE	IF	CITATIONS
73	Cancer immunosurveillance by CD8 T cells. <i>F1000Research</i> , 2020, 9, 80.	0.8	11
74	ANCA associated glomerulonephritis in a patient with mixed connective tissue disease. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 410-411.	0.5	9
75	Serine/threonine phosphatase PP2A is essential for optimal B cell function. <i>JCI Insight</i> , 2020, 5, .	2.3	9
76	Brief Report: Increased expression of a short splice variant of CTLA4 exacerbates lupus in MRL/lpr mice. <i>Arthritis and Rheumatism</i> , 2013, 65, 764-769.	6.7	7
77	Fas/FasL Signaling Regulates CD8 Expression During Exposure to Self-Antigens. <i>Frontiers in Immunology</i> , 2021, 12, 635862.	2.2	6
78	The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway. <i>Clinical Immunology</i> , 2020, 212, 108240.	1.4	5
79	Protein phosphatase 2A B55 ^{Δ2} limits CD8+ T cell lifespan following cytokine withdrawal. <i>Journal of Clinical Investigation</i> , 2020, 130, 5989-6004.	3.9	5
80	Identity loss due to chronic fingertip ischemia. <i>Journal of Rheumatology</i> , 2004, 31, 1222-4.	1.0	4
81	Chronic Destructive Elbow Arthropathy Associated With Hydroxyapatite Crystals in a Patient With Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2006, 12, 194-195.	0.5	3
82	A TWEAK in lupus nephritis. <i>Clinical Immunology</i> , 2012, 145, 139-140.	1.4	3
83	Regulatory T cells as modulators of B cell antibody production. <i>Clinical Immunology</i> , 2011, 140, 216-217.	1.4	2
84	Dysregulation of the serine/threonine phosphatase PP2A contributes to autoimmunity. <i>Arthritis Research and Therapy</i> , 2012, 14, .	1.6	2
85	T Cells. , 2013, , 96-103.		2
86	Intrathecal formation of anticardiolipin antibodies in a patient with SLE-related relapsing longitudinal myelitis: a possible pathogenic connection. <i>Lupus</i> , 2018, 27, 2292-2295.	0.8	2
87	Quantitative and Qualitatively Normal Regulatory T Cells are Not Capable of Inducing Suppression in SLE Patients Due to T Cell Resistance. <i>Clinical Immunology</i> , 2007, 123, S101-S102.	1.4	1
88	The Role of Interleukin-17 in Systemic Lupus Erythematosus. , 2011, , 391-400.		1
89	Editorial: Mechanisms by Which SLE-Associated Genetic Variants Contribute to SLE Pathogenesis. <i>Frontiers in Immunology</i> , 2019, 10, 2808.	2.2	1
90	Pathogenesis of lupus. , 2011, , 1289-1294.e1.		1

#	ARTICLE	IF	CITATIONS
91	Dysregulated protein kinase/phosphatase networks in SLE T cells. <i>Clinical Immunology</i> , 2022, 236, 108952.	1.4	1
92	Modulation of In Vivo T Cell Activation by an Acetylcholine-Esterase Inhibitor in Patients Chronically Infected with HIV. <i>Clinical Immunology</i> , 2007, 123, S46.	1.4	0
93	T-Cells and Systemic Lupus Erythematosus. , 2011, , 129-142.		0
94	Systemic Lupus Erythematosus and Systemic Autoimmunity. , 2014, , .		0
95	THU0057â€¦Kn-93, an Inhibitor of Calcium/Calmodulin-Dependent Protein Kinase Iv, Promotes Generation and Function of Foxp3+ Regulatory T Cells in Mrl/Lpr Mice. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 195.3-196.	0.5	0
96	Stat3 and Stat5 govern IL-10 expression in T cells through trans-activation and epigenetic remodelling in health and disease. <i>Molecular and Cellular Pediatrics</i> , 2014, 1, A17.	1.0	0
97	FRI0018â€¦CAMK4 Inhibition Prevents Recruitment of IL-17 Producing Cells to Target Organs Through CCR6/CCL20 Axis in TH17 Driven Inflammatory Diseases. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 425.1-425.	0.5	0
98	T Cells. , 2016, , 113-119.		0
99	Intrathecal anti-suprabasin antibodies in SLE, a cause of local concern?. <i>Clinical Immunology</i> , 2018, 193, 131-132.	1.4	0
100	T Cells. , 2019, , 116-124.		0
101	AMPK Phosphorylation Effect of Genistein Is Independent of GPR30. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa045_117.	0.1	0
102	T cells. , 2021, , 123-129.		0
103	Unwinding the Long Road that leads to Understanding Autoimmunity. <i>Revista De Investigacion Clinica</i> , 2021, 73, 297-301.	0.2	0
104	Systemic Lupus Erythematosus, Pathogenesis. , 2014, , 1178-1184.		0
105	Lessons from SjÃ¶rgrenâ€™s syndrome etiopathogenesis: Novel cellular and molecular targets. <i>World Journal of Immunology</i> , 2015, 5, 152.	0.5	0
106	Pathogenesis of lupus. , 2015, , 1082-1087.		0
107	Ethical Considerations in Animal Research: The Principle of 3R's. <i>Revista De Investigacion Clinica</i> , 2020, 73, .	0.2	0